Kiran Divi

We have not lost a single customer or even a any loss in volume.

DIS has strategically decided that we will not look at generic part of peptide synthesis. We are right now fully occupied with the amount of CS projects we have.

I cannot put a label saying this is API or peptide or specific therapeutic category. All I can say is it belongs to a CS side of the business and we believe if all regulatory approvals and qualifications take place on time in the next one to two years you should see commercial benefit.

We are witnessing increased traction from global innovators who are actively seeking partners that can offer both scalability and reliability in a changing global supply chain landscape.

We are seeing a healthy pipeline of RFPs and customer site visits alongside multiple active projects progressing through R&D, pilot, and validation stages.

We are experiencing pricing pressure across our large volume products like naproxen, gabapentin, dextromethorphan. But we being one of the largest producer and player and having long-term contracts with our customers, we are able to maintain sustainable market share, and in fact, growing in those products.

On the peptide business, initially we were just manufacturing protected amino acids... But now we have started working on tetramer and decamer, basically 4-chain amino acids, 10-chain amino acids, either through solid phase or liquid phase.

We are seeing a lot of opportunities coming our way. With BIOSECURE Act, we are seeing more number of phase II and phase III molecules than what we saw before.